XML 85 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue from Contracts with Customers (Tables)
12 Months Ended
Dec. 31, 2020
Disclosure Of Revenue From Contracts With Customers [Abstract]  
Summary of Disaggregation of Revenues from Contracts with Customers

Set out below is the disaggregation of the Group’s revenues from contracts with customers:

 

 

 

Years ended

December 31,

(in thousands)

 

2020

2019

2018

Research & development revenues from collaborations

 

€178,849

€84,428

€101,837

Pfizer Inc.

 

121,597

14,348

7,173

Genentech Inc.

 

49,195

64,026

49,536

Shanghai Fosun Pharmaceutical (Group) Co., Ltd

 

5,074

-

-

Other

 

2,983

6,054

45,128

Commercial revenues

 

303,476

24,161

25,738

COVID-19 vaccine revenues

 

270,490

-

-

Sales to collaboration partner*

 

61,460

-

-

Direct product sales to BioNTech customers

 

20,553

-

-

Share of collaboration partner's gross profit

 

188,477

-

-

Other sales

 

32,986

24,161

25,738

Total

 

€482,325

€108,589

€127,575

*Represents sales to collaboration partner of products manufactured by BioNTech.

 

The revenues from contracts with customers disclosed above were recognized as follows:

 

 

 

Years ended

December 31,

(in thousands)

 

2020

2019

2018

Timing of revenue recognition

 

 

 

 

Goods and services transferred at a point in time

 

€108,840

€16,955

€22,828

Goods and services transferred over time

 

373,485

91,634

104,747

Total

 

€482,325

€108,589

€127,575

Summary of Contract Balances

(in thousands)

 

December 31,

2020

December 31,

2019

Trade receivables

 

€165,468

€11,913

Contract liabilities

 

371,475

190,692

 

Summary of Revenue Recognized

Set out below is the amount of revenue recognized for the periods indicated:

 

 

Years ended

December 31,

(in thousands)

 

2020

2019

2018

Amounts included in contract liabilities at the beginning of the year

 

€58,895

€84,112

€59,583

 

Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied)

The contract liabilities allocated to the remaining performance obligations from collaboration or commercial supply agreements (unsatisfied or partially unsatisfied) as at year-end are as follows:

(in thousands)

 

December 31,

2020

December 31,

2019

Within one year

 

€299,583

€93,583

More than one year

 

71,892

97,109

Total

 

€371,475

€190,692